Inactive Instrument

News Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

French Drugmaker Ipsen Concludes Albireo Pharma Takeover	23-03-02	MT
ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-03-02	AQ
Albireo Pharma, Inc. Announces Board Changes	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index	23-03-02	CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.	23-02-28	CI
Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance	23-02-22	MT
Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome	23-02-15	AQ
Albireo Pharma's Bylvay Granted Priority Review for Rare Genetic Disorder Alagille Syndrome Treatment	23-02-14	MT
Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome	23-02-14	DJ
ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-02-14	AQ
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome	23-02-14	AQ
Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application	23-02-14	CI
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	23-01-24	BU
Insider Sell: Albireo Pharma	23-01-20	MT
Guggenheim Downgrades Albireo Pharma to Neutral From Buy	23-01-11	MT
Cowen Downgrades Albireo Pharma to Market Perform From Outperform, Adjusts Price Target to $48 From $68	23-01-11	MT
Jefferies Downgrades Albireo Pharma to Hold From Buy, Adjusts Price Target to $42 From $49	23-01-11	MT
North American Morning Briefing : Stock Futures -2-	23-01-11	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Summary

Filters